Jci_page_head_homepage_01 Jci_page_head_homepage_02
David Patsouris, Stéphane Mandard, Peter J. Voshol, Pascal Escher, Nguan Soon Tan, Louis M. Havekes, Wolfgang Koenig, Winfried März, Sherrie Tafuri, Walter Wahli, Michael Müller, Sander Kersten
Published in Volume 114, Issue 1
J Clin Invest. 2004; 114(1):94–103 doi:10.1172/JCI20468
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 3

PPARγ and PPARβ/δ agonists induce cGPDH gene expression in adipocytes. (A) 3T3-L1 adipocytes at day 10 of differentiation were treated with the PPARγ agonists ciglitazone (25 μM) or rosiglitazone (Rosi) (5 μM), or the PPARβ agonist L165041 (7.5 μM), and mRNA expression of the indicated genes was determined by Q-PCR. Results are expressed as percentage of control (DMSO). One-way ANOVA indicated that differences in expression were statistically significant for all four genes (P < 0.05). (B) Human SGBS adipocytes at day 13 of differentiation were treated with PPARγ agonist rosiglitazone (1 μM) or PPARβ agonists L165041 (2.5 μM). Expression of the indicated genes was determined by Q-PCR. One-way ANOVA indicated that differences in expression were statistically significant for all three genes (P < 0.05). (C) Expression of cGPDH in WAT of PPARγ+/– and PPARβ/δ–/– mice, as determined by Q-PCR. Differences were statistically significant (Student’s t test, P < 0.05). (D) Expression of cGPDH in WAT of wild-type mice fed 0.01% rosiglitazone or 0.025% L165041, as determined by Q-PCR. The effect of rosiglitazone was statistically significant (Student’s t test, P < 0.01). Error bars represent SEM.